Skip to content

Study · Observational study · n = 33 · 2013

3 results

Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty.

Lewis KA, Eugster EA

The Journal of pediatrics3 Oct 2012Cited by 29 (Europe PMC)

PMID23040793 (opens in a new tab)PMCIDPMC4094029 (opens in a new tab)DOI10.1016/j.jpeds.2012.08.038 (opens in a new tab)PepBankPUB-23040793
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    No child receiving histrelin for CPP had clinical evidence of pubertal progression.

    In plain wordsNo child receiving histrelin for CPP showed clinical pubertal progression.

    Peptide
    Histrelin
    Outcome
    Not applicableClinical pubertal progression
    Study

    n = 33

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No patient had clinical evidence of pubertal progression.
    3 context sentences
    Summary · context
    This was a prospective, uncontrolled, observational study at a pediatric endocrinology tertiary center.
    Summary · context
    Thirty-three children (26 girls; mean age 7.2 ± 2.5 years) treated with a histrelin implant for CPP were enrolled.
    Summary · context
    A random US LH measurement was obtained at 6 months, and a gonadotropin-releasing hormone analog stimulation test was performed at 12 months.
  2. 02HumanObservational studyEfficacy outcome

    In children with CPP receiving histrelin, all 31 tested patients had peak stimulated LH below 4 IU/L.

    In plain wordsIn children with CPP receiving histrelin, all tested children had suppressed stimulated LH.

    Peptide
    Histrelin
    Outcome
    DecreaseStimulated LH suppression
    Study

    n = 31

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Peak stimulated LH in all tested patients
    < 4 IU/L
    GnRH analog stimulation test, all 31 patients tested

    Source sentences

    Summary
    In contrast, gonadotropin-releasing hormone analog stimulation tests revealed complete hypothalamic-pituitary-gonadal axis suppression (peak LH <4 IU/L) in all 31 patients who underwent testing.
    3 context sentences
    Summary · context
    This was a prospective, uncontrolled, observational study at a pediatric endocrinology tertiary center.
    Summary · context
    Thirty-three children (26 girls; mean age 7.2 ± 2.5 years) treated with a histrelin implant for CPP were enrolled.
    Summary · context
    A random US LH measurement was obtained at 6 months, and a gonadotropin-releasing hormone analog stimulation test was performed at 12 months.
  3. 03HumanObservational studyEfficacy outcome

    In children with CPP receiving histrelin, random LH exceeded the prepubertal range in 59% (17 of 29) at 6 months.

    In plain wordsIn children with CPP receiving histrelin, random LH remained above the prepubertal range in 59% at 6 months.

    Peptide
    Histrelin
    Outcome
    Not applicableRandom LH above prepubertal range
    Study

    n = 29

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Patients with random US LH above prepubertal range
    59%
    6 months, 17 of 29 patients
    Patients with random US LH above prepubertal range
    17 patients
    6 months, of 29 patients

    Source sentences

    Summary
    In 59% of the patients (17 of 29), the 6-month random US LH exceeded the prepubertal range of ≤0.3 IU/L.
    3 context sentences
    Summary · context
    This was a prospective, uncontrolled, observational study at a pediatric endocrinology tertiary center.
    Summary · context
    Thirty-three children (26 girls; mean age 7.2 ± 2.5 years) treated with a histrelin implant for CPP were enrolled.
    Summary · context
    A random US LH measurement was obtained at 6 months, and a gonadotropin-releasing hormone analog stimulation test was performed at 12 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.